These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 37926243)

  • 1. Innovative drug delivery strategies to the CNS for the treatment of multiple sclerosis.
    Mwema A; Muccioli GG; des Rieux A
    J Control Release; 2023 Dec; 364():435-457. PubMed ID: 37926243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Convolutions in the rendition of nose to brain therapeutics from bench to bedside: Feats & fallacies.
    Goel H; Kalra V; Verma SK; Dubey SK; Tiwary AK
    J Control Release; 2022 Jan; 341():782-811. PubMed ID: 34906605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updated Progress of Nanocarrier-Based Intranasal Drug Delivery Systems for Treatment of Brain Diseases.
    Fan Y; Chen M; Zhang J; Maincent P; Xia X; Wu W
    Crit Rev Ther Drug Carrier Syst; 2018; 35(5):433-467. PubMed ID: 30317945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Versatile Nanoparticulate Systems as a Prosperous Platform for Targeted Nose-Brain Drug Delivery.
    Taha E; Shetta A; Nour SA; Naguib MJ; Mamdouh W
    Mol Pharm; 2024 Mar; 21(3):999-1014. PubMed ID: 38329097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal Drug Delivery: A Non-Invasive Approach for the Better Delivery of Neurotherapeutics.
    Kumar H; Mishra G; Sharma AK; Gothwal A; Kesharwani P; Gupta U
    Pharm Nanotechnol; 2017; 5(3):203-214. PubMed ID: 28521670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nose-to-brain drug delivery for the treatment of CNS disease: New development and strategies.
    Du L; Chen L; Liu F; Wang W; Huang H
    Int Rev Neurobiol; 2023; 171():255-297. PubMed ID: 37783558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights into direct nose to brain delivery: current status and future perspective.
    Mittal D; Ali A; Md S; Baboota S; Sahni JK; Ali J
    Drug Deliv; 2014 Mar; 21(2):75-86. PubMed ID: 24102636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting.
    Pardeshi CV; Belgamwar VS
    Expert Opin Drug Deliv; 2013 Jul; 10(7):957-72. PubMed ID: 23586809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The blood-brain barrier and nasal drug delivery to the central nervous system.
    Miyake MM; Bleier BS
    Am J Rhinol Allergy; 2015; 29(2):124-7. PubMed ID: 25785753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approaches for CNS delivery of drugs - nose to brain targeting of antiretroviral agents as a potential attempt for complete elimination of major reservoir site of HIV to aid AIDS treatment.
    Gupta S; Kesarla R; Omri A
    Expert Opin Drug Deliv; 2019 Mar; 16(3):287-300. PubMed ID: 30779602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of Noninvasive Drug Delivery Systems to the Brain for the Treatment of Brain/Central Nervous System Diseases].
    Kanazawa T
    Yakugaku Zasshi; 2018; 138(4):443-450. PubMed ID: 29607986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-depth Mechanism, Challenges, and Opportunities of Delivering Therapeutics in Brain Using Intranasal Route.
    Ghosh A; Majie A; Karmakar V; Chatterjee K; Chakraborty S; Pandey M; Jain N; Roy Sarkar S; Nair AB; Gorain B
    AAPS PharmSciTech; 2024 May; 25(5):96. PubMed ID: 38710855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug Delivery Systems and Strategies to Overcome the Barriers of Brain.
    Garg Y; Kapoor DN; Sharma AK; Bhatia A
    Curr Pharm Des; 2022; 28(8):619-641. PubMed ID: 34951356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acting centrally or peripherally: A renewed interest in the central nervous system penetration of disease-modifying drugs in multiple sclerosis.
    Correale J; Halfon MJ; Jack D; Rubstein A; Villa A
    Mult Scler Relat Disord; 2021 Nov; 56():103264. PubMed ID: 34547609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Access to the CNS: Strategies to overcome the BBB.
    Sánchez-Dengra B; González-Álvarez I; Bermejo M; González-Álvarez M
    Int J Pharm; 2023 Apr; 636():122759. PubMed ID: 36801479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders.
    Islam SU; Shehzad A; Ahmed MB; Lee YS
    Molecules; 2020 Apr; 25(8):. PubMed ID: 32326318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal drug delivery to the central nervous system: present status and future outlook.
    Tayebati SK; Nwankwo IE; Amenta F
    Curr Pharm Des; 2013; 19(3):510-26. PubMed ID: 23116337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood-Brain Barrier (BBB)-Crossing Strategies for Improved Treatment of CNS Disorders.
    Zhang W
    Handb Exp Pharmacol; 2024; 284():213-230. PubMed ID: 37528323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation and physiological factors influencing CNS delivery upon intranasal administration.
    Vyas TK; Tiwari SB; Amiji MM
    Crit Rev Ther Drug Carrier Syst; 2006; 23(4):319-47. PubMed ID: 17341201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CNS drug delivery systems: novel approaches.
    Pathan SA; Iqbal Z; Zaidi SM; Talegaonkar S; Vohra D; Jain GK; Azeem A; Jain N; Lalani JR; Khar RK; Ahmad FJ
    Recent Pat Drug Deliv Formul; 2009 Jan; 3(1):71-89. PubMed ID: 19149731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.